














Angiographic and Procedural Characteristics in Frail Older Patients with Non-ST Elevation Acute Coronary Syndrome

Benjamin Beska ^{1,2} Hanna Ratcovich ^{1,3} Alan Bagnall ^{1,2} Amy Burrell,¹ Richard Edwards ² Mohaned Egred ^{1,2} Rebecca Jordan ⁴ Amina Khan ⁵ Greg B Mills ¹ Emma Morrison,¹ Daniell Edward Raharjo ¹ Fateh Singh ⁶ Chris Wilkinson ^{1,7} Azfar Zaman ^{1,2} and Vijay Kunadian ^{1,2}

1. Translational and Clinical Research Institute, Newcastle University, Newcastle, UK; 2. Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; 3. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 4. Worcestershire Acute Hospitals NHS Trust, Worcester, UK; 5. Leeds Teaching Hospitals NHS Trust, Leeds, UK; 6. Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK; 7. Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK

Abstract

Background: Angiographic and procedural characteristics stratified by frailty status are not known in older patients with non-ST elevation acute coronary syndrome (NSTEMACS). We evaluated angiographic and procedural characteristics in older adults with NSTEMACS by frailty category, as well as associations of baseline and residual SYNTAX scores with long-term outcomes. **Methods:** In this study, 271 NSTEMACS patients aged ≥ 75 years underwent coronary angiography. Frailty was assessed using the Fried criteria. Angiographic analysis was performed using QAngio[®] XA Medis in a core laboratory. Major adverse cardiovascular events (MACE) consisted of all-cause mortality, MI, stroke or transient ischaemic attack, repeat unplanned revascularisation and significant bleeding. **Results:** Mean (\pm SD) patient age was 80.5 ± 4.9 years. Compared with robust patients, patients with frailty had more severe culprit lesion calcification (OR 5.40; 95% CI [1.75–16.8]; $p=0.03$). In addition, patients with frailty had a smaller mean improvement in culprit lesion stenosis after percutaneous coronary intervention (50.6%; 95% CI [45.7–55.6]) than robust patients (58.6%; 95% CI [53.5–63.7]; $p=0.042$). There was no association between frailty phenotype and completeness of revascularisation (OR 0.83; 95% CI [0.36–1.93]; $p=0.67$). A high baseline SYNTAX score (≥ 33) was associated with adjusted (age and sex) 5-year MACE (HR 1.40; 95% CI [1.08–1.81]; $p=0.01$), as was a high residual SYNTAX score (≥ 8 ; adjusted HR 1.22; 95% CI [1.00–1.49]; $p=0.047$). **Conclusion:** Frail adults presenting with NSTEMACS have more severe culprit lesion calcification. Frail adults were just as likely as robust patients to receive complete revascularisation. Baseline and residual SYNTAX score were associated with MACE at 5 years.

Keywords

Angiography, acute coronary syndrome, older adults, frailty

Disclosure: The authors have no conflicts of interest to declare.

Informed consent to participate and publish: All patients provided written informed consent.

Data availability statement: The data that support the findings of this study are available from the Chief Investigator at vijay.kunadian@newcastle.ac.uk and the Study Sponsor Newcastle Joint Research Office, The Newcastle upon Tyne Hospitals NHS Foundation Trust (Level 1, Regent Point, Regent Farm Road, Gosforth, Newcastle upon Tyne, NE3 3HD, UK. E: trust.r&d@nuth.nhs.uk).

Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the National Research Ethics Service (12/NE/0160). This study is registered with ClinicalTrials.gov (ID NCT01933581).

Trial registration number: Clinicaltrials.gov ID: NCT01933581.

Funding: This research was supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre based at Newcastle-upon-Tyne Hospitals NHS Foundation Trust and Newcastle University. VK has received research funding from the British Heart Foundation (CS/15/7/31679). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author contributions: Conceptualisation: VK; formal analysis: BB, RJ, AK, GBM, EM, DER, FS; funding acquisition: VK; investigation: BB, AB, AB, RE, ME, RJ, AK, GBM, EM, DER, FS, AZ; project administration: VK; supervision: VK; writing – original draft preparation: BB; writing – review and editing: BB, HR, AB, AB, RE, ME, RJ, AK, GBM, EM, DER, FS, CW, AZ, VK; data curation: BB; methodology: BB, CW; resources: VK; visualisation: BB, CW.

Received: 2 June 2022 **Accepted:** 10 September 2022 **Citation:** *Interventional Cardiology* 2023;18:e04. **DOI:** <https://doi.org/10.15420/icr.2022.20>

Correspondence: Vijay Kunadian, 4th Floor William Leech Building, Newcastle University Medical School, Newcastle upon Tyne, NE2 4HH, UK. E: vijay.kunadian@newcastle.ac.uk

Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Increasing age is an important risk factor for acute coronary syndrome (ACS). Population ageing means that the prevalence of ACS, and non-ST elevation acute coronary syndrome (NSTEMACS) in particular, is rising.^{1,2}

However, the evidence base to guide the optimal management of older people with NSTEMACS is limited, particularly if they have concomitant frailty.^{3,4} Frailty describes a state of increased vulnerability to poor

resolution after a stressor and is common in older adults with NSTEMI.^{5,6}

In general, older people less frequently receive guideline-recommended management, including coronary angiography, following NSTEMI than younger patients. This variation in care may reflect uncertainties in both the evidence to support an invasive approach in this population and international guideline recommendations.^{7–12}

Previous data have shown that frailty is a better predictor of adverse outcomes following ACS than chronological age alone.^{13–15} Yet, we lack data on the association between frailty, coronary angiography features and clinical outcomes in older patients with NSTEMI; these data are needed to support decision-making in this population. Therefore, in the present prospective cohort study we evaluated the angiographic and procedural characteristics in older adults with NSTEMI by frailty category. We also evaluated the association of baseline and residual SYNTAX scores with long-term major adverse cardiovascular events (MACE).

Methods

Setting and Participants

This is a prespecified subgroup analysis of the study to Improve Cardiovascular Outcomes in high-risk patients with acute coronary syndrome (ICON1). The full study design has been published elsewhere.¹⁶ The ICON1 study was a multicentre prospective cohort study of patients aged ≥ 75 years with NSTEMI referred for invasive coronary angiography to either Freeman Hospital, Newcastle, UK (receiving patients referred from six district hospitals) or James Cook University Hospital, Middlesbrough, UK (receiving patients referred from five district hospitals). Patients were recruited between November 2012 and December 2015.¹⁶ All patients underwent coronary angiography and guideline-recommended management of NSTEMI, in accordance with current European Society of Cardiology guidelines.³

The study received ethics approval from the National Research Ethics Service (12/NE/0160). Participants provided written informed consent, and the study was conducted in accordance with the Declaration of Helsinki.

Variables and Data Sources

Participants were evaluated for frailty at the time of admission by the research team using the Fried criteria, which consist of subjective and objective assessments of slowness, weakness, low physical activity, exhaustion and weight loss.¹⁷ Patients were considered robust if no criteria were met, prefrail if one or two criteria were met and frail if three or more criteria were met.

Baseline data were collected during the index presentation and are reported by frailty category. The data collected included population demographics (age and sex), clinical characteristics (BMI, smoking status, Global Risk of Acute Coronary Event 2.0 score, New York Heart Association [NYHA] grade, Canadian Cardiovascular Society Angina Score), frailty (according to Fried criteria), comorbidity (according to the Charlson comorbidity index), past medical history, laboratory tests at admission and baseline medical history (antithrombotic medication, statins, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β -blocker, calcium channel blocker, anticoagulant medication).

Procedural data included femoral or radial access, the use of a glycoprotein IIb/IIIa inhibitor or unfractionated heparin, contrast volume, radiation dose and duration of procedure. Angiographic characteristics included vessel

dominance, number of diseased vessels and number of lesions. Percutaneous coronary intervention (PCI)-related data were collected (i.e. number of treated vessels, complexity of the PCI procedure [rotablation or laser], number of stents and stent type). The SYNTAX score was calculated according to standard SYNTAX score criteria (www.syntaxscore.org).¹⁸

Angiographic data were analysed using QAngio[®] XA Medis in a core laboratory at Newcastle University by at least two independent researchers, blinded to all other data. Angiographic quantitative and qualitative data were reported for the culprit lesion and were stratified by frailty phenotype. Quantitative angiographic analysis was performed on the angiographic frame with maximal stenosis, with hand-drawn contours around the lumen diameter and the lumen diameter and lesion length at the site of each diseased vessel. The analyses were conducted according to standard criteria using previous definitions and included: culprit artery, culprit vessel quantitative analysis (lesion diameter stenosis, length, vessel diameter, lesion area, minimum lumen diameter) and culprit qualitative analysis (calcification grade, eccentric, diffuse ostial or bifurcation lesion, ulcer, pulsatile or slow flow, collaterals and collateral score [0–3], thrombus and thrombus score [0–5], and lesion complexity [Type A, Type B1, Type B2 or Type C]).^{19–22} For patients undergoing PCI for a culprit lesion, SYNTAX scores were calculated before and after PCI (baseline and residual SYNTAX score, respectively) and stratified by frailty phenotype. Baseline SYNTAX scores were classified as low (0–22), moderate (23–32) and high (≥ 33), whereas residual SYNTAX scores were divided into three groups according to clinical relevance: ‘complete revascularisation’ (0), ‘acceptable incomplete revascularisation’ (1–7) and ‘unacceptable incomplete revascularisation’ (≥ 8).²³

Five-year follow-up data were collected from electronic primary and secondary care patient records, linked to National Health Service (NHS) Digital. MACE was a composite of all-cause mortality, MI, stroke or transient ischaemic attack, repeat unplanned revascularisation and significant bleeding (defined as Bleeding Academic Research Consortium [BARC] Type 2 or greater).¹⁶

Statistical Analysis

Baseline characteristics, procedural and angiographic features and culprit lesion quantitative and qualitative angiographic analyses are reported by frailty phenotype. Categorical data are presented as numbers and percentages and were compared using the Chi-squared (χ^2) test or Fisher’s exact test. Continuous variables were tested for normal distribution using the Kolmogorov–Smirnov test, with normality defined as $p > 0.05$. Variables that were not normally distributed had a Q-Q plot drawn and inspected. Normally distributed variables are presented as the mean \pm SD and were compared using independent samples t-tests. Non-normally distributed variables are presented as the median and interquartile range (IQR) and were compared using the Kruskal–Wallis one-way test of variance.

Paired student’s t-tests were used to analyse the mean difference in quantitative angiographic variables measured in the culprit artery before and after PCI stratified by frailty phenotype.

Logistic regression was used to model the association between frailty and baseline and residual SYNTAX scores, presented as unadjusted ORs with 95% CIs. Two adjusted logistic regression models were constructed: one model adjusted for age and sex, and the second model adjusted for baseline characteristics that differed between frailty groups at baseline (age, sex, previous MI, previous transient ischaemic attack or stroke, heart failure, anaemia).

To evaluate whether procedural success modifies the relationship in clinical outcomes in this older cohort in terms of composite endpoint in 5-year follow-up, Cox proportional hazards models were used with residual SYNTAX score included. Unadjusted HRs with 95% CI are reported, alongside those adjusted for age and sex.

All analyses were performed using SPSS Statistics version 27 (IBM Corporation), with significance set at $p \leq 0.05$ (*Supplementary Material Table 5*).

Results

Baseline Characteristics

The ICON1 study cohort comprised 297 patients; the 271 (91.2%) patients for whom angiographic data were available were included in the present substudy (*Supplementary Material Figure 1*). Of these 271 patients, 53 (19.6%) were robust, 145 (53.5%) were prefrail and 73 (26.9%) were frail. Mean age increased with increasing frailty (78.7 ± 4.9 , 80.7 ± 4.5 and 81.3 ± 5.2 years for the robust, prefrail and frail groups, respectively), with a decreasing proportion of males with increasing frailty ($n=39$ [73.6%], $n=89$ [61.4%] and $n=36$ [49.3%] in the robust, prefrail and frail groups, respectively). Robust patients were less often admitted with a NYHA class of III or IV ($n=4$ [7.5%], $n=23$ [15.9%] and $n=50$ [31.5%] in the robust, prefrail and frail groups, respectively; $p=0.001$; *Table 1*). There were no differences in medications among frailty phenotypes (*Supplementary Material Table 1*).

Baseline Angiographic Analysis

Vascular access via the femoral (as opposed to radial) artery was less common in robust than prefrail and frail patients ($n=2$ [3.8%] versus $n=16$ [11%] and $n=14$ [29.2%], respectively; $p=0.02$). The mean SYNTAX score increased with increasing frailty (10 ± 7.0 , 13 ± 10.0 and 15 ± 11.0 in the robust, prefrail and frail groups, respectively; $p=0.03$), indicating more complex coronary artery disease (*Table 2*).

Culprit Lesion Angiographic Analysis

Of the 229 patients with culprit lesions, 211 (92.1%) had culprit lesion PCI performed. Robust patients had significantly smaller culprit lesion vessel diameter than prefrail and frail patients (2.84 ± 0.6 versus 2.82 ± 0.74 and 3.17 ± 0.92 mm, respectively; $p=0.008$), as well as significantly smaller culprit lesion minimum lumen diameter (0.85 ± 0.44 versus 0.90 ± 0.51 and 1.08 ± 0.53 mm, respectively; $p=0.025$) and a lower proportion of severe culprit lesion calcification ($n=4$ [8.7%] versus $n=25$ [20.7%] and $n=21$ [33.9%], respectively; $p=0.032$; *Table 3*). Frailty category was not associated with the likelihood of culprit lesion PCI being performed ($n=42$ [91.3%], $n=110$ [90.9%] and $n=59$ [95.2%] in the robust, prefrail and frail groups, respectively; $p=0.58$). There were no differences between frailty groups and post-PCI culprit lesion quantitative angiographic measurements (*Supplementary Material Table 2*).

Improvements in mean culprit lesion diameter stenosis were significantly greater in robust patients (-58.6% ; 95% CI $[-53.5, -63.7]$) than in prefrail (-55.7% ; 95% CI $[-52.7, -58.6]$) and frail (-50.6% ; 95% CI $[-45.7, -55.6]$) patients ($p=0.042$; *Table 4*). Overall, there was a low periprocedural complication rate ($n=12$; 5.6%) with no significant difference between the robust, prefrail and frail groups ($n=2$ [4.8%], $n=8$ [7.3%] and $n=2$ [3.4%], respectively; $p=0.56$; *Supplementary Material Table 3*).

A residual SYNTAX score was calculated for 187 (81.7%) patients. The cohort median residual SYNTAX score was 0 (IQR 0–9.0), with 56% of the whole cohort having a residual SYNTAX score of 0. There was no significant difference in median residual SYNTAX score between frailty

phenotypes, with all frailty groups having a median score of 0 (IQR 0–9.0; $p=0.76$; *Table 2*).

Multivariate Logistic Models of the Association Between Frailty and Angiographic Parameters

Frail patients had a greater than fivefold increase in the odds of severe culprit lesion calcification compared with robust patients (unadjusted OR 5.40; 95% CI [1.75–16.8]; $p=0.03$). In fully adjusted analyses, there was no association between frailty and a high (≥ 33) baseline SYNTAX score (adjusted OR 2.03; $p=0.74$) or frailty and a residual SYNTAX score of zero (adjusted OR 2.59; 95% CI [0.46–14.4]; $p=0.27$; *Table 5*; *Supplementary Material Table 4*).

Clinical Outcomes at the 5-Year Follow-Up

In all, 264 (97.4%) patients in the angiographic cohort completed the 5-year follow-up and are included in the exploratory cohort analysis. The median follow-up was 61.5 months. MACE occurred in 161 (60.9%) patients. For the whole cohort, a high (≥ 33) baseline SYNTAX score was associated with MACE in an unadjusted univariate analysis (HR 1.44; 95% CI [1.12–1.84]; $p=0.004$) and this association remained significant after adjustment for age and sex (HR 1.40; 95% CI [1.08–1.81]; $p=0.01$). A residual SYNTAX score ≥ 8 was associated with MACE in an unadjusted univariate analysis (HR 1.23; 95% CI [1.01–1.50]; $p=0.037$) and the association remained significant after adjustment for age and sex (HR 1.22; 95% CI [1.00–1.49]; $p=0.047$).

Discussion

In this prospective cohort study of older adults with NSTEMI, frail adults presenting with NSTEMI had more severe culprit lesion calcification, but this did not affect the likelihood of these patients receiving complete revascularisation. Both high baseline and residual SYNTAX scores were associated with adverse outcomes at 5 years.

International treatment guidelines increasingly recommend a patient-centred approach, with an assessment of frailty status when managing older adults with NSTEMI.^{11,12} Despite the fact that this cohort is increasingly a larger proportion of those presenting with NSTEMI, older patients are under-represented in clinical research, meaning evidence to guide decision-making is limited.³ This study presents the first analysis of the impact of the frailty phenotype on angiographic and procedural characteristics and their association on long-term adverse outcomes.

It has been previously hypothesised that the value of the SYNTAX score in predicting long-term adverse outcomes in the very oldest patients may be outweighed by other factors not yet defined.²⁴ The data we present show that, independent of age, the frailest patients have a statistically significantly higher baseline SYNTAX score. However, further large-cohort studies are needed to determine the clinical significance of the 5-point difference in SYNTAX scores between frail and robust patients. The frailty phenotype may play an important and previously unmeasured role in the complexity of coronary artery disease found at the time of coronary angiography. Reverse causality is possible, with the presence of complex coronary artery disease contributing to the development of frailty through limitation in physical activity and subsequent slowness, both of which are criteria of the Fried frailty phenotype.¹⁷ In an exploratory analysis, there was an association between a high baseline SYNTAX score and the 5-year incidence of MACE. As the population ages and the prevalence of the frailty phenotype increases, clinical and angiographic scoring systems that remain accurate when applied to this cohort are important. The ongoing British Heart Foundation SENIOR-RITA trial (NCT03052036) is a

Table 1: Baseline Characteristics Stratified by Frailty Phenotype

	Total (n=271)	Robust (n=53)	Prefrail (n=145)	Frail (n=73)	P value
Demographics					
Age (years)	80.5 ± 4.9	78.7 ± 4.9	80.7 ± 4.5	81.3 ± 5.2	0.006
Male sex	164 (60.5)	39 (73.6)	89 (61.4)	36 (49.3)	0.02
Clinical characteristics					
BMI (kg/m ²)	26.9 [24.2–29.4]	27.5 [26.0–28.9]	26.5 [24.1–29.4]	27.2 [23.9–29.9]	0.67
Smoking					
Current smoker	20 (7.4)	3 (5.7)	11 (7.6)	6 (8.2)	0.85
Ex-smoker	134 (49.4)	26 (49.1)	67 (46.2)	41 (56.2)	0.38
Never-smoker	115 (42.4)	24 (45.3)	65 (44.8)	26 (35.6)	0.39
GRACE 2.0 score	129 [115–141]	121 [111–134]	129 [116–138]	135 [124–152]	<0.001
NYHA Class III or IV	50 (18.5)	4 (7.5)	23 (15.9)	23 (31.5)	0.001
CCS III or IV	35 (12.9)	6 (11.3)	15 (10.3)	14 (19.2)	0.172
Frailty and comorbidity					
CCI (points)	5.2 [4.0–6.0]	4.0 [3.0–5.0]	5.0 [4.0–6.0]	6.0 [5.0–7.0]	<0.0001
Fried frailty criteria					
Weight loss	73 (26.9)	0	29 (20.0)	44 (60.3)	<0.0001
Energy	81 (29.9)	0	30 (20.7)	51 (69.9)	<0.0001
Activity	96 (35.4)	0	34 (23.4)	62 (84.9)	<0.0001
Weakness	170 (63.0)	1 (1.9)	104 (72.2)	65 (89.0)	<0.0001
Slow walking	39 (14.6)	0	8 (5.6)	31 (43.1)	<0.0001
Past medical history					
Hypertension	200 (73.8)	38 (71.7)	102 (70.3)	60 (82.2)	0.16
Diabetes	64 (23.6)	6 (11.3)	39 (26.9)	19 (26.0)	0.63
Hypercholesterolaemia	156 (57.6)	31 (58.5)	82 (56.6)	43 (58.9)	0.94
Ischaemic heart disease	84 (31.2)	16 (31.4)	43 (29.7)	25 (34.2)	0.79
Renal impairment	51 (18.8)	5 (9.4)	28 (19.3)	18 (24.7)	0.10
Previous MI	84 (31.0)	12 (22.6)	41 (28.3)	31 (42.5)	0.04
Previous angina	109 (40.2)	14 (26.4)	61 (42.1)	34 (46.6)	0.06
Previous PCI	53 (19.6)	8 (15.1)	25 (17.2)	20 (27.4)	0.13
Previous CABG	6 (2.2)	1 (1.9)	4 (2.8)	1 (1.4)	0.79
AF	35 (12.9)	6 (11.3)	14 (9.7)	15 (20.5)	0.07
PVD	26 (9.6)	4 (7.5)	13 (9.0)	9 (12.3)	0.62
Previous TIA/stroke	45 (16.6)	3 (5.7)	23 (15.9)	19 (26.0)	0.009
COPD	49 (18.1)	5 (9.4)	26 (17.9)	18 (24.7)	0.09
Malignancy	24 (8.9)	6 (11.3)	11 (7.6)	7 (9.6)	0.69
Heart failure	20 (7.4)	1 (1.9)	8 (5.5)	11 (15.1)	0.009
Peptic ulcer disease	14 (5.2)	2 (3.8)	9 (6.2)	3 (4.1)	0.71
Bleeding problems	6 (2.2)	0	4 (2.8)	2 (2.7)	0.47
Anaemia	22 (8.1)	0	12 (8.3)	10 (13.7)	0.02
Laboratory tests					
Haemoglobin (g/l)	13.2 ± 1.9	14.1 ± 1.7	13.1 ± 1.9	12.5 ± 1.8	<0.001
White cell count (×10 ⁹ /l)	7.90 [6.60–9.70]	7.80 [6.50–9.20]	8.10 [6.70–9.70]	6.70 [6.90–9.70]	0.65
Creatinine (µmol/l)	94.0 [78.0–116.0]	101.0 [78.0–116.0]	94.0 [78.0–114.0]	92.0 [92.0–77.0]	0.85
eGFR (ml/min/1.73 m ²)	51.6 [41.9–65.7]	56.1 [46.7–70.1]	52.4 [41.1–65.4]	49.1 [37.9–62.8]	0.08
Glucose (mmol/l)	6.40 [5.50–8.20]	6.50 [5.60–7.70]	6.25 [5.40–8.30]	6.50 [5.60–9.10]	0.46
Total cholesterol (mmol/l)	4.10 [3.30–5.00]	4.0 [3.30–5.10]	4.10 [3.40–4.80]	4.30 [3.20–4.90]	0.85

Table 1: Cont.

	Total (n=271)	Robust (n=53)	Prefrail (n=145)	Frail (n=73)	P value
Peak troponin (ng/l)	121 [40.0–451.0]	158.0 [50.0–534.0]	162.0 [41.0–455.0]	84.0 [31.0–326.0]	0.23
hs-CRP (mg/l)	3.70 [1.30–9.20]	2.10 [0.90–5.40]	4.30 [1.40–10.6]	4.50 [1.50–9.70]	0.04

Unless indicated otherwise, data are given as the mean ± SD, median [interquartile range] or n (%). CABG = coronary artery bypass graft; CCI = Charlson comorbidity index; CCS = Canadian Cardiovascular Society angina score; COPD = chronic obstructive pulmonary disease; eGFR = estimated glomerular filtration rate; GRACE = Global Registry of Acute Coronary Events; hs-CRP = high-sensitivity C-reactive protein; NYHA = New York Heart Association score; PCI = percutaneous coronary intervention; PVD = peripheral vascular disease; TIA = transient ischaemic attack.

Table 2: Procedural and Angiographic Features Stratified by Frailty Phenotype

	Total (n=271)	Robust (n=53)	Prefrail (n=145)	Frail (n=73)	P value
Clinical presentation					
NSTEMI	225 (83.0)	47 (88.7)	118 (81.4)	60 (82.2)	0.47
Unstable angina	46 (17.0)	6 (11.3)	27 (18.6)	13 (17.8)	0.47
Procedural characteristics					
Radial access	239 (88.2)	51 (96.2)	129 (89.0)	59 (80.8)	0.02
Femoral access	32 (11.8)	2 (3.8)	16 (11.0)	14 (29.2)	0.02
GP2b3a inhibitor	21 (7.7)	2 (3.8)	12 (8.3)	7 (9.6)	0.45
Periprocedural UFH	264 (97.4)	52 (98.1)	141 (97.2)	71 (97.3)	0.48
Contrast volume (ml)	162 ± 78	168 ± 75	158 ± 81	166 ± 75	0.65
Radiation dose (cGy.cm ²)	5659 [5101]	6921 [6025]	7009 [4799]	6728 [4882]	0.56
Duration of PCI (min)	61 [31]	63 [43]	58 [45]	65 [38]	0.41
Angiographic characteristics					
Vessel dominance					0.27
Left dominant	44 (16.2)	7 (13.2)	22 (15.2)	15 (20.5)	
Right dominant	218 (80.4)	42 (79.2)	119 (82.1)	57 (78.1)	
Co-dominant	9 (3.3)	4 (7.5)	4 (2.8)	1 (1.4)	
Angiographic disease pattern					0.30
None	22 (8.1)	4 (7.5)	14 (9.7)	4 (5.5)	
Single-vessel disease	84 (31.0)	14 (26.4)	49 (33.8)	21 (28.8)	
Two-vessel disease	105 (38.7)	27 (50.9)	47 (32.4)	31 (42.5)	
Triple-vessel disease	60 (22.1)	8 (15.1)	35 (24.1)	17 (23.3)	
No. lesions					0.67
0	22 (8.1)	4 (7.5)	14 (9.7)	4 (5.5)	
1	29 (29.2)	14 (29.4)	48 (33.2)	17 (23.3)	
2	81 (29.9)	19 (35.8)	40 (27.6)	22 (30.1)	
≥3	89 (32.8)	16 (30.2)	43 (29.7)	30 (41.1)	
Single-vessel PCI	164 (60.5)	33 (62.3)	86 (59.3)	45 (61.6)	0.91
Multivessel PCI	62 (22.9)	12 (22.6)	31 (21.4)	19 (26.0)	0.74
No. non-culprit lesions	1 [2]	1 [2]	1 [2]	1 [1]	0.66
PCI					
Left main stem	16 (5.9)	2 (3.8)	7 (4.8)	7 (9.6)	0.28
LAD	132 (48.7)	24 (45.3)	70 (48.3)	38 (52.1)	0.75
LCx	70 (25.8)	14 (26.4)	33 (22.8)	23 (31.5)	0.38
RCA	83 (30.6)	19 (35.8)	43 (29.7)	31 (28.8)	0.65
Complex PCI					
Rotablation	12 (4.4)	1 (1.9)	3 (2.1)	8 (11.0)	0.013
Laser and rotablation	2 (0.7)	1 (1.9)	0	1 (1.4)	

Table 2: Cont.

	Total (n=271)	Robust (n=53)	Prefrail (n=145)	Frail (n=73)	P value
No. stents	1 [1]	2 [2]	1 [1]	1 [1]	0.15
Stent type					0.99
Drug-eluting stent	221 (77.9)	42 (79.2)	112 (77.2)	57 (78.1)	
Bare-metal stent	5 (1.8)	1 (1.9)	3 (2.1)	1 (1.4)	
Both stent types	3 (1.1)	1 (1.9)	1 (0.7)	1 (1.4)	
Baseline SYNTAX score	13 ± 10.0	10 ± 7.0	13 ± 10.0	15 ± 11.0	0.03
Baseline SYNTAX score tertiles					
Low (0–22)	224 (82.7)	50 (94.3)	119 (82.1)	55 (75.3)	0.02
Medium (23–32)	32 (11.8)	2 (3.8)	17 (11.7)	13 (17.8)	0.055
High (≥33)	15 (5.5)	1 (1.9)	9 (6.2)	5 (6.8)	0.42
Residual SYNTAX score [†]	0 [0–9.0]	0 [0–9.0]	0 [0–9.0]	0 [0–9.0]	0.76
Residual SYNTAX score group [‡]					0.94
Complete revascularisation (0)	105 (56.1)	24 (58.5)	54 (55.7)	27 (55.1)	
Incomplete revascularisation					
Acceptable (1–7)	30 (16.0)	5 (12.2)	17 (17.5)	8 (16.3)	
Unacceptable (≥8)	52 (27.8)	12 (29.3)	26 (26.8)	14 (28.6)	

Unless indicated otherwise, data are given as the mean ± SD, median [interquartile range] or n (%). [†] Only performed in patients with a culprit lesion that underwent PCI. GP2b3a = glycoprotein IIb/IIIa; LAD = left anterior descending artery; LCx = left circumflex artery; NSTEMI = non-ST elevation MI; PCI = percutaneous coronary intervention; RCA = right coronary artery; UFH = unfractionated heparin.

Table 3: Baseline Culprit Lesion Quantitative and Qualitative Angiographic Analysis Stratified by Frailty Phenotype

	Total (n=229)	Robust (n=46)	Prefrail (n=121)	Frail (n=62)	P value
Culprit artery					0.29
Left main stem	11 (4.8)	2 (4.3)	3 (2.5)	6 (9.7)	
LAD disease	108 (47.2)	23 (50.0)	60 (49.6)	25 (40.3)	
LCx disease	46 (20.1)	7 (15.2)	23 (19.0)	16 (25.8)	
RCA disease	64 (27.9)	14 (30.4)	35 (28.9)	15 (24.2)	
Culprit vessel quantitative analysis					
Culprit lesion completely occluded	1 (0.4)	0 (0)	1 (0.8)	0 (0)	0.64
Culprit lesion diameter stenosis (%)	67.9 ± 14.2	69.6 ± 14.3	68.1 ± 15.0	66.4 ± 12.4	0.49
Culprit lesion length (mm)	14.6 ± 10.3	13.9 ± 8.3	14.6 ± 10.8	15.1 ± 10.8	0.85
Culprit lesion vessel diameter (mm)	2.92 ± 0.78	2.84 ± 0.6	2.82 ± 0.74	3.17 ± 0.92	0.008
Culprit lesion area (mm ²)	88.0 ± 9.1	88.9 ± 9.2	88.1 ± 9.2	87.2 ± 8.9	0.63
Culprit lesion minimum lumen diameter (mm)	0.94 ± 0.51	0.85 ± 0.44	0.90 ± 0.51	1.08 ± 0.53	0.025
Culprit vessel qualitative analysis					
Calcification					0.032
None	92 (40.2)	21 (45.7)	54 (44.6)	17 (27.4)	
Mild	45 (19.7)	13 (28.3)	21 (17.4)	11 (17.7)	
Moderate	42 (18.3)	8 (17.4)	21 (17.4)	13 (21.0)	
Severe	50 (21.8)	4 (8.7)	25 (20.7)	21 (33.9)	
Eccentric lesion	127 (55.5)	17 (37.0)	67 (55.4)	43 (69.4)	0.004
Diffuse	41 (17.9)	7 (15.2)	23 (19.0)	11 (17.7)	0.85
Ostial lesion	24 (10.0)	3 (6.5)	11 (9.1)	9 (14.5)	0.30
Bifurcation lesion	64 (27.9)	7 (15.2)	33 (27.3)	24 (38.7)	0.035
Ulcer	5 (2.2)	2 (4.3)	2 (1.7)	1 (1.6)	0.53
Pulsatile flow	5 (2.2)	1 (2.2)	4 (3.3)	0 (0)	0.56
Slow flow	23 (10.0)	6 (13.0)	16 (13.2)	1 (1.6)	0.11
Collaterals present	7 (3.1)	3 (6.5)	4 (3.3)	0 (0)	0.15

Table 3: Cont.

	Total (n=229)	Robust (n=46)	Prefrail (n=121)	Frail (n=62)	P value
Collateral score					0.38
0	222 (96.9)	43 (93.5)	117 (3.3)	62 (100)	
1	4 (1.7)	2 (4.3)	2 (1.7)	0 (0)	
2	3 (1.3)	1 (2.2)	2 (1.7)	0 (0)	
Thrombus present	18 (7.9)	5 (10.9)	9 (7.4)	4 (6.5)	0.78
Thrombus score					0.54
0	211 (92.1)	41 (89.1)	112 (92.6)	58 (93.5)	
1	7 (3.1)	2 (4.3)	4 (3.3)	1 (1.6)	
2	3 (1.3)	0 (0)	2 (1.7)	1 (1.6)	
3	6 (2.6)	2 (4.3)	3 (2.5)	1 (1.6)	
4	1 (0.4)	0 (0)	0 (0)	1 (1.6)	
5	1 (0.4)	2 (2.2)	0 (0)	0 (0)	
Lesion complexity					0.09
A	15 (6.6)	4 (8.7)	10 (8.3)	1 (1.6)	
B1	66 (28.8)	17 (37.0)	35 (28.9)	14 (22.6)	
B2	95 (41.5)	14 (30.4)	46 (38.0)	35 (56.5)	
C	53 (23.1)	11 (23.9)	30 (24.8)	12 (19.4)	

Unless indicated otherwise, data are given as the mean ± SD, median [interquartile range] or n (%). LAD = left anterior descending artery; LCx = left circumflex artery; RCA = right coronary artery.

Table 4: Mean Differences in Quantitative Angiographic Analysis Before and After PCI in the Culprit Lesion, Stratified by Frailty Phenotype

	Robust (n=42)	Prefrail (n=110)	Frail (n=59)	P value*
Culprit lesion diameter stenosis	-58.6 (-53.5, -63.7)	-55.7 (-52.7, -58.6)	-50.6 (-45.7, -55.6)	0.042
Culprit lesion vessel diameter	+0.28 (0.13, 0.43)	+0.26 (0.14, 0.38)	+0.14 (0.23, 0.50)	0.58
Culprit lesion area	+67.6 (63.0, 72.1)	+64.1 (61.4, 66.8)	+60.2 (54.9, 65.5)	0.26
Culprit lesion minimum lumen diameter	+2.0 (2.10, 1.80)	+1.81 (1.93, 1.68)	+1.6 (1.83, 1.40)	0.13

Unless indicated otherwise, data show the mean difference with 95% CIs in parentheses. Statistically significant (p≤0.05) results are bolded. All mean differences were statistically significant at the p<0.0001 level. *P value for the difference in mean difference between frailty phenotypes. PCI = percutaneous coronary intervention.

large (n=1600) randomised trial investigating the role of invasive management in all-comer frail, older adults with NSTEMI. The analysis will include a preplanned subgroup analysis by frailty phenotype in addition to qualitative and quantitative angiographic analyses of participant angiograms, which will provide data on angiographic and procedural characteristics and clinical outcomes in a randomised control trial setting.

Frail adults had more than fivefold increased odds of severe culprit lesion calcification compared with non-frail patients. Frail patients also were more likely to require complex PCI, likely as a consequence of increased culprit calcification. Although vessel calcification is an established age-dependent process, the age-independent association with frailty is a novel finding.²⁵ The underlying pathophysiological processes are unclear; however, inflammation is considered a key process in atherosclerosis, in addition to coronary artery calcification, and is increasingly considered as key in the pathogenesis of the frailty phenotype.²⁵⁻²⁷ In a previously published analysis of the ICON1 study cohort, non-robust patients had a greater presence of high-risk lesions on virtual history intravascular ultrasound imaging, with a 2.81 increased adjusted odds (95% CI [1.06–7.48]; p=0.039) of the presence of thin cap fibroatheroma, independent of age.²⁸ It is increasingly clear that frail adults presenting with non-ST

segment elevation MI have more procedurally challenging angiographic characteristics, independent of age.

In a recently published long-term follow-up analysis of the ICON1 study cohort, frail patients had a significantly adjusted increased hazard of incidence of the primary composite outcome compared with robust patients (HR 1.81; 95% CI [1.00–3.27]; p=0.048), with similar findings for adults in the ICON1 study cohort with a higher burden of multimorbidity.^{29,30} Further work is needed to investigate the effects of the angiographic characteristics on outcomes in these frail, multimorbid patients in the context of large, well-powered studies allowing granular analysis.

Notably, 22 (8.1%) patients, 4 (5.5%) of whom were frail, had no culprit lesion identified and therefore are classified as MI with non-obstructive coronary arteries (MINOCA). This is a novel finding of the rate of MINOCA in this older, frail age group with NSTEMI. This presentation of ischaemia may be contributed to epicardial vasospasm and coronary microvascular dysfunction, but further research is needed, particularly in older adults.³¹

The risk–benefit ratio of coronary intervention in these patients is unclear and interventional cardiologists, therefore, need to be selective when undertaking PCI. Despite frail patients having a high SYNTAX

Table 5: Unadjusted Logistic Regression Models for the Association Between Frailty and Angiographic Characteristics

Variable	Frail versus robust	
	OR (95% CI)	P value
Femoral access	3.98 (1.28–12.5)	0.017
Radial access	0.25 (0.08–0.78)	0.017
Severe culprit lesion calcification	5.40 (1.75–16.8)	0.03
Eccentric lesion	1.73 (0.58–5.16)	0.32
Bifurcation lesion	1.61 (0.39–6.63)	0.51
Baseline SYNTAX score		
Low (0–22)	Reference	–
Medium (23–32)	5.91 (1.27–27.5)	0.024
High (≥33)	4.54 (0.51–40.3)	0.09
Residual SYNTAX score		
Incomplete unacceptable (>8)	Reference	–
Incomplete acceptable (1–7)	1.05 (0.30–3.70)	0.93
Complete revascularisation (0)	0.83 (0.36–1.93)	0.67

score at baseline, with an associated higher likelihood of complex coronary artery disease, this did not affect procedural complications, which were similar between frailty phenotypes. In addition, after PCI was performed, residual SYNTAX scores were similar between frailty groups. The residual SYNTAX score has been shown to predict 5-year mortality following PCI; therefore, these findings may suggest that despite an initially adverse angiographic profile and a more challenging procedure for the operator, the operators achieved complete revascularisation equally in all patients, regardless of their frailty status.²³ In our exploratory analysis, a higher residual SYNTAX score

was associated with MACE after 5 years, but it is important to note that this analysis was not formally powered.

There are some limitations to this study. This study recruited patients that had already been referred for coronary angiography; therefore, the very oldest and frailest patients may have been excluded at the referring hospitals. A large limitation of this study is the small number of patients, particularly at the extremes of Fried frailty (i.e. in the robust and frail groups). Consequently, the CIs for the OR of certain angiographic characteristics (particularly calcification) are very wide. The overall SYNTAX score for the cohort is also low. Despite this, frail older patients are difficult to recruit to clinical trials in cardiology, and these findings should be considered hypothesis generating. Further detailed angiographic analysis in a large cohort of older patients is preplanned in the ongoing British Heart Foundation SENIOR-RITA Trial.

In conclusion, frail adults presenting with NSTEMI have more severe baseline coronary artery calcification than robust adults, independent of age. Frail adults were just as likely as robust patients to receive complete revascularisation. In an exploratory analysis, baseline and residual SYNTAX scores were associated with MACE at 5 years. □

Clinical Perspective

- Frail patients have more adverse angiographic characteristics than robust adults, particularly severe culprit lesion calcification, independent of age.
- Despite more complex coronary artery disease, frail patients are just as likely as robust patients to receive successful complete revascularisation.
- In exploratory analysis, baseline and residual SYNTAX scores in older frail adults referred for invasive treatment for NSTEMI were associated with MACE at 5 years.

1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics – 2018 update: a report from the American Heart Association. *Circulation* 2018;137:e67–492. <https://doi.org/10.1161/CIR.0000000000000558>; PMID: 29386200.

2. National Institute for Cardiovascular Outcomes Research (NICOR). Myocardial ischaemia national audit project. 2019. <https://www.nicor.org.uk/wp-content/uploads/2019/09/MINAP-2019-Summary-Report-final.pdf> (accessed 2 June 2022).

3. Sinclair H, Batty JA, Qiu W, Kunadian V. Engaging older patients in cardiovascular research: observational analysis of the ICON-1 study. *Open Heart* 2016;3:e000436. <https://doi.org/10.1136/openhrt-2016-000436>; PMID: 27547431.

4. Mills GB, Ratcovich H, Adams-Hall J, et al. Is the contemporary care of the older persons with acute coronary syndrome evidence-based? *Eur Heart J Open* 2022;2:oeab044. <https://doi.org/10.1093/ehjopen/oeab044>; PMID: 35919658.

5. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. *Lancet* 2013;381:752–62. [https://doi.org/10.1016/S0140-6736\(12\)62167-9](https://doi.org/10.1016/S0140-6736(12)62167-9).

6. Patel A, Goodman SG, Yan AT, et al. Frailty and outcomes after myocardial infarction: insights from the CONCORDANCE Registry. *J Am Heart Assoc* 2018;7:e009859. <https://doi.org/10.1161/JAHA.118.009859>; PMID: 30371219.

7. Devlin G, Gore JM, Elliott J, et al. Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. *Eur Heart J* 2008;29:1275–82. <https://doi.org/10.1093/eurheartj/ehf124>; PMID: 18387940.

8. Tegn N, Abdelnoor M, Aaberge L, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. *Lancet* 2016;387:1057–65. [https://doi.org/10.1016/S0140-6736\(15\)01166-6](https://doi.org/10.1016/S0140-6736(15)01166-6); PMID: 26794722.

9. Sanchis J, Núñez E, Barrabés JA, et al. Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction. *Eur J Intern Med* 2016;35:89–94. <https://doi.org/10.1016/j.ejim.2016.07.003>; PMID: 27423981.

10. Savonitto S, Cavallini C, Petronio AS, et al. Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial. *JACC Cardiovasc Interv* 2012;5:906–16. <https://doi.org/10.1016/j.jcin.2012.06.008>; PMID: 22995877.

11. Collet JP, Thiele H, Barbato E, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2021;42:1289–367. <https://doi.org/10.1093/eurheartj/ehaa575>; PMID: 32860058.

12. Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. *Circulation* 2007;115:2549–69. <https://doi.org/10.1161/CIRCULATIONAHA.107.182615>; PMID: 17502590.

13. Murali-Krishnan R, Iqbal J, Rowe R, et al. Impact of frailty on outcomes after percutaneous coronary intervention: a prospective cohort study. *Open Heart* 2015;2:e000294. <https://doi.org/10.1136/openhrt-2015-000294>; PMID: 26380099.

14. Batty J, Qiu W, Gu S, et al. One-year clinical outcomes in older patients with non-ST elevation acute coronary syndrome undergoing coronary angiography: an analysis of the ICON1 study. *Int J Cardiol* 2019;274:45–51. <https://doi.org/10.1016/j.ijcard.2018.09.086>; PMID: 30287058.

15. Walker DM, Gale CP, Lip G, et al. Editor's choice – frailty and the management of patients with acute cardiovascular disease: a position paper from the Acute Cardiovascular Care Association. *Eur Heart J Acute Cardiovasc Care* 2018;7:176–93. <https://doi.org/10.1177/2048872618758931>; PMID: 29451402.

16. Kunadian V, Neely RD, Sinclair H, et al. Study to Improve Cardiovascular Outcomes in high-risk older patients (ICON1) with acute coronary syndrome: study design and protocol of a prospective observational study. *BMJ Open* 2016;6:e012091. <https://doi.org/10.1136/bmjopen-2016-012091>; PMID: 27554105.

17. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56:M146–56. <https://doi.org/10.1093/gerona/56.3.M146>; PMID: 11253156.

18. Head SJ, Farrow V, Serruys PW, Kappetein AP. The SYNTAX score and its clinical implications. *Heart* 2014;100:169–77. <https://doi.org/10.1136/heartjnl-2012-302482>; PMID: 23539552.

19. Habib GB, Heibig J, Forman SA, et al. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I Thrombolysis In Myocardial Infarction (TIMI) trial. The TIMI Investigators. *Circulation* 1991;83:739–46. <https://doi.org/10.1161/01.CIR.83.3.739>; PMID: 1900223.

20. Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy.

- Circulation* 2001;103:2550–4. <https://doi.org/10.1161/01.CIR.103.21.2550>; PMID: 11382722.
21. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee on percutaneous transluminal coronary angioplasty). *Circulation* 1988;78:486–502. <https://doi.org/10.1161/01.CIR.78.2.486>; PMID: 2969312.
 22. Ellis SG, Roubin GS, King SB, 3rd, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. *Circulation* 1988;77:372–9. <https://doi.org/10.1161/01.CIR.77.2.372>; PMID: 2962787.
 23. Farooq V, Serruys PW, Bourantas CV, et al. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. *Circulation* 2013;128:141–51. <https://doi.org/10.1161/CIRCULATIONAHA.113.001803>; PMID: 23766350.
 24. Eickhoff M, Schüpke S, Khandoga A, et al. Age-dependent impact of the SYNTAX-score on longer-term mortality after percutaneous coronary intervention in an all-comer population. *J Geriatr Cardiol* 2018;15:559–66. <https://doi.org/10.11909/j.issn.1671-5411.2018.09.009>; PMID: 30344539.
 25. Li JJ, Zhu CG, Yu B, et al. The role of inflammation in coronary artery calcification. *Ageing Res Rev* 2007;6:263–70. <https://doi.org/10.1016/j.arr.2007.09.001>; PMID: 17964226.
 26. Tiong AY, Brieger D. Inflammation and coronary artery disease. *Am Heart J* 2005;150:11–8. <https://doi.org/10.1016/j.ahj.2004.12.019>; PMID: 16084145.
 27. Soysal P, Stubbs B, Lucato P, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. *Ageing Res Rev* 2016;31:1–8. <https://doi.org/10.1016/j.arr.2016.08.006>; PMID: 27592340.
 28. Gu SZ, Qiu W, Batty JA, et al. Coronary artery lesion phenotype in frail older patients with non-ST-elevation acute coronary syndrome undergoing invasive care. *EuroIntervention* 2019;15:e261–8. <https://doi.org/10.4244/EIJ-D-18-00848>; PMID: 30777840.
 29. Ratcovich H, Beska B, Mills G, et al. Five-year clinical outcomes in patients with frailty aged ≥75 years with non-ST elevation acute coronary syndrome undergoing invasive management. *Eur Heart J Open* 2022;2:oeac035. <https://doi.org/10.1093/ehjopen/oeac035>; PMID: 35919345.
 30. Beska B, Mills GB, Ratcovich H, et al. Impact of multimorbidity on long-term outcomes in older adults with non-ST elevation acute coronary syndrome in the north east of England: a multi-centre cohort study of patients undergoing invasive care. *BMJ Open* 2022;12:e061830. <https://doi.org/10.1136/bmjopen-2022-061830>; PMID: 35882457.
 31. Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. *Eur Heart J* 2017;38:143–53. <https://doi.org/10.1093/eurheartj/ehw149>; PMID: 28158518.